Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non‐small cell lung cancer in real‐world practice

• Published in: The clinical respiratory journal 2024-05, Vol.18 (5), p.e13761-n/a
• Main Authors: Huang, Xiaojie, Pang, Guanchao, Mao, Zhirong, Li, Baizhou, Teng, Zhihua, Yang, Yan, Qiu, Zijian, Chen, Xiuxiu, Wang, Pingli
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Carcinoma, Non-Small-Cell Lung - therapy; Chemotherapy; Disease-Free Survival; Female; Humans; immunochemotherapy; Immunotherapy; Immunotherapy - methods; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Lung Neoplasms - therapy; Male; Medical prognosis; Middle Aged; neoadjuvant; Neoadjuvant Therapy - methods; Neoplasm Staging; non‐small cell lung cancer; Original; Pneumonectomy - methods; Retrospective Studies; Treatment Outcome; treatment response
• ISSN: 1752-6981; 1752-699X
• DOI: 10.1111/crj.13761

Background In order to improve survival outcomes in resectable non‐small cell lung cancer (NSCLC), strategies for neoadjuvant therapy need to be revisited. We evaluated and compared the efficacy of different neoadjuvant therapeutic modalities in a real‐world setting. Methods A total of 258 patients with clinical stage IIA to IIIB NSCLC was included. All the patients underwent surgical resection after one to four cycles of neoadjuvant treatment consisting of chemotherapy (83), immunotherapy (23), and immunotherapy plus chemotherapy (152). Results The radiologic response rate in the combined immunochemotherapy group was 67.8%, higher than that of 48.2% in the chemotherapy group and 4.3% in the immunotherapy group (p